Rx License-Rx

TAB-2697

Species-specific Nucleic Acid Detection Assay for Fungi

This invention pertains to nucleic acid-based assays for the detection of Aspergillus and other filamentous fungi. Assays cover the species-specific detection and diagnosis of infection by Aspergillus , Fusarium , Mucor , Penecillium , Rhizomucor , Absidia , Cunninghamella , Pseudallescheria or Sporthrix in a subject. This can reduce identification time from several days by conventional culture methods to a matter of hours. Furthermore, genus-specific probes are also provided for Aspergillus , Fusarium and Mucor , in addition to an "all-fungus" nucleic acid probe. This technology is readily adaptable as kits used for species-specific identification of opportunistic pathogen infections or possible work/home contamination. Commercial applications: Directing antifungal drug therapy for improved patient outcomes. Detection, discrimination of fungal species from biological samples. Addressing secondary infections of immunosuppressed...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Ophthalmology

Indication: Ophthalmology

Modality: Diagnostic / Biomarker

Focus tags: Ophthalmology, Oncology, Infectious Disease, Cardiometabolic, Inflammation

Technology tags: Diagnostic / Biomarker, Biomanufacturing

Mechanism:

Development stage: Preclinical

Patent status: Expired; Abandoned

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Ophthalmology. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Ophthalmology. Public description: This invention pertains to nucleic acid-based assays for the detection of Aspergillus and other filamentous fungi. Assays cover the species-specific detection and diagnosis of infection by Aspergillus , Fusarium , Mucor , Penecillium .

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

Oncology remains highly partnerable: Pharma buyers still pay attention when an asset can be tied to biomarkers, combinations, resistance biology, or a defined tumor segment.

The eye can create faster proof: Local delivery, imaging endpoints, and smaller patient groups can make ophthalmology assets easier to de-risk than broad systemic programs.

Can sell into pharma before reimbursement: A biomarker or AI tool can create value as trial enrichment, patient stratification, or translational support before becoming a regulated diagnostic.

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Validation can be harder than the demo: Models and biomarkers need locked datasets, external validation, clinical utility, data rights, and a regulatory/reimbursement plan.

Competitive field may be crowded: Oncology buyers will ask why this is better than existing modalities, combinations, and biomarker strategies already in the clinic.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Ophthalmology wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Merck — Checkpoint-franchise adjacency and combination-trial appetite. AstraZeneca — Oncology breadth plus interest in biomarker-defined populations. Roche / Genentech — Diagnostics plus oncology translational machinery.

Development Strategy to Increase PoS

First indication: Ophthalmology

Study design: Retrospective locked-dataset validation followed by one prospective pharma enrichment pilot.

Key experiments Validate the AI-optimized pivot: Reframe as a localized orphan-retina or front-of-eye precision program Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Reframe as a localized orphan-retina or front-of-eye precision program

Best next experiment: Run the smallest independent study that validates: Switch from systemic exposure to intravitreal, topical, or depot delivery and use OCT/ERG/imaging biomarkers as early go/no-go endpoints.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.